Thiazolidinedione
Thiazolidinediones
Pathophysiology and Natural History
Oral Agents
Diabetes drugs helping to drive rise in US medication expenditures
Annual expenditures for diabetes medications more than tripled in the U.S. from 2011 to 2020, and the increase played a role in an overall rise in money spent on prescription drugs, according to study findings.
SGLT2 inhibitors preferred for adults with type 2 diabetes and heart failure
HOUSTON — SGLT2 inhibitors should be the first choice of therapy for adults with type 2 diabetes and heart failure, according to two speakers at the Association of Diabetes Care and Education Specialists annual meeting.
Top in endocrinology: First-line diabetes therapies, DIY artificial pancreas use policies
Data has indicated thiazolidinedione pioglitazone and GLP-1 receptor agonists improve beta-cell function in patients with diabetes, prompting a meeting presenter to suggest both drugs be used as first-line therapies for the disease.
Two diabetes drug classes can increase, maintain beta-cell function
The thiazolidinedione pioglitazone and GLP-1 receptor agonists are the only two diabetes drugs proved to increase and maintain beta-cell function, and both should be first-line therapies for patients, according to a speaker.
List prices for newer diabetes drugs up to 360 times higher than older ones
Medicare Part D list prices in 2019 for the new, “novel” generation of second-line drugs for glycemic control sometimes cost hundreds of dollars more than the older “traditional” formulations of drugs, according to researchers.
Metformin prescribed to only half of patients with type 2 diabetes and CKD, newer medications less utilized
More health care providers prescribe metformin to patients with type 2 diabetes and chronic kidney disease than other diabetes medications, with most prescriptions coming from primary care physicians, according to findings published in the Journal of Diabetes and its Complications.